Retrospective Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2016; 22(15): 4034-4040
Published online Apr 21, 2016. doi: 10.3748/wjg.v22.i15.4034
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma
Jiang Li, Yu Hou, Xiao-Bei Cai, Bin Liu
Jiang Li, Xiao-Bei Cai, Bin Liu, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China
Yu Hou, Department of Oncology Radiotherapy, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan province, Kunming 650181, Yunnan Province, China
Author contributions: Li J and Hou Y contributed equally to this work; Li J and Hou Y designed the study and analyzed the data; Li J, Hou Y, and Cai XB acquired data and drafted the manuscript; Li J, Hou Y, and Liu B defined the intellectual content; Cai XB researched literature; Liu B provided administrative, technical, and material support and critically revised the manuscript; all authors guarantee the integrity of the entire study and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the First Affiliated Hospital of Kunming Medical University Institutional Review Board.
Informed consent statement: This is a retrospective study, informed consent is not required.
Conflict-of-interest statement: None declared.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Bin Liu, MD, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming 650032, Yunnan Province, China.
Telephone: +86-871-65355319 Fax: +86-871-65357191
Received: July 1, 2015
Peer-review started: July 4, 2015
First decision: August 26, 2015
Revised: October 27, 2015
Accepted: December 30, 2015
Article in press: December 30, 2015
Published online: April 21, 2016
Core Tip

Core tip: Barcelona Clinic Liver Cancer stage C patients with portal vein thrombus and Child-Pugh class A liver function who received sorafenib after surgical resection had significantly longer overall survival (37 mo vs 20 mo, P = 0.01) and significantly longer time to progression compared to patients who received only resection (29 mo vs 22 mo, P = 0.041). Our data suggested that better outcomes can be achieved with sorafenib after surgical resection, rather than sorafenib monotherapy.